SCHEMBL5363755

SCHEMBL5363755

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cccs1)C(=O)N2

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.66
SRC P12931 10/20 0.55
KDR P35968 6/20 0.54
CDK2 P24941 2/20 0.54
NTRK1 P04629 2/20 0.53
FCER2 P06734 1/20 0.52
SYK P43405 1/20 0.52
NTRK3 Q16288 1/20 0.52
NTRK2 Q16620 1/20 0.52
PAK4 O96013 1/20 0.48
JAK3 P52333 1/20 0.48
LCK P06239 5/20 0.48
FYN P06241 5/20 0.48
YES1 P07947 5/20 0.48
FGFR1 P11362 5/20 0.48
PDGFRB P09619 4/20 0.48
AURKA O14965 1/20 0.45
MAP4K1 Q92918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140809 0.83 SRC (0.54) PDPK1SRCKDRCDK2NTRK1
SCHEMBL5364795 0.82 SRC (0.55) PDPK1SRCKDRCDK2NTRK1
SCHEMBL5361859 0.82 SRC (0.55) PDPK1SRCKDRCDK2NTRK1
SCHEMBL5358922 0.81 PDPK1 (0.63) PDPK1NTRK1PAK4JAK3MAP4K1
SCHEMBL5369843 0.81 SRC (0.59) SRCKDRCDK2NTRK1FCER2
SCHEMBL24967151 0.81 PDPK1 (0.74) PDPK1NTRK1PAK4JAK3MAP4K1
SCHEMBL17674469 0.81 PDPK1 (0.74) PDPK1NTRK1PAK4JAK3MAP4K1
SCHEMBL17679355 0.81 PDPK1 (0.74) PDPK1NTRK1PAK4JAK3MAP4K1
SCHEMBL5363032 0.81 SRC (0.54) PDPK1SRCKDRCDK2NTRK1
SCHEMBL5359785 0.81 SRC (0.54) SRCKDRCDK2NTRK1FCER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDPK1 31/4885SRC 189/4885KDR 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.